File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Human ESC/iPSC-based 'omics' and bioinformatics for translational research

TitleHuman ESC/iPSC-based 'omics' and bioinformatics for translational research
Authors
Issue Date2012
Citation
Drug Discovery Today: Disease Models, 2012, v. 9 n. 4, p. e161-e170 How to Cite?
AbstractThe establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells. © 2012 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/195143
ISSN
2015 SCImago Journal Rankings: 0.286

 

DC FieldValueLanguage
dc.contributor.authorMüller, GA-
dc.contributor.authorTarasov, KV-
dc.contributor.authorGundry, RL-
dc.contributor.authorBoheler, KR-
dc.date.accessioned2014-02-25T01:40:14Z-
dc.date.available2014-02-25T01:40:14Z-
dc.date.issued2012-
dc.identifier.citationDrug Discovery Today: Disease Models, 2012, v. 9 n. 4, p. e161-e170-
dc.identifier.issn1740-6757-
dc.identifier.urihttp://hdl.handle.net/10722/195143-
dc.description.abstractThe establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell-based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells. © 2012 Elsevier Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofDrug Discovery Today: Disease Models-
dc.titleHuman ESC/iPSC-based 'omics' and bioinformatics for translational research-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ddmod.2012.02.003-
dc.identifier.scopuseid_2-s2.0-84876690042-
dc.identifier.volume9-
dc.identifier.issue4-
dc.identifier.spagee161-
dc.identifier.epagee170-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats